Abstract
The secretion of a number of enterohormones is disordered in the critically ill which may mediate abnormalities in motility and glycaemia. However, these mediators can also potentially serve a protective role, dampening inflammation and modulating the enteral immune response. There are over 30 recognised enterohormones, and therapeutic manipulation of specific enterohormones or their receptors is a burgeoning area of critical care research with promising preclinical data and an increasing number of small clinical trials. Further characterisation of the effect of critical illness on the endocrine gut and how it can be manipulated to improve outcomes in critical illness warrants evaluation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rehfeld JF (2012) Beginnings: a reflection on the history of gastrointestinal endocrinology. Regul Pept 177(Suppl):S1–S5
Schmidt WE (1997) The intestine, an endocrine organ. Digestion 58(Suppl 1):56–58
Thompson JS (1995) The intestinal response to critical illness. Am J Gastroenterol 90(2):190–200
Deane A, Chapman MJ, Fraser RJ, Horowitz M (2010) Bench-to-bedside review: the gut as an endocrine organ in the critically ill. Crit Care 14(5):228
Parker BA, Doran S, Wishart J, Horowitz M, Chapman IM (2005) Effects of small intestinal and gastric glucose administration on the suppression of plasma ghrelin concentrations in healthy older men and women. Clin Endocrinol 62(5):539–546
Crona D, MacLaren R (2012) Gastrointestinal hormone concentrations associated with gastric feeding in critically ill patients. JPEN J Parenter Enteral Nutr 36(2):189–196
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402(6762):656–660
Muller TD, Nogueiras R, Andermann ML, Andrews ZB, Anker SD, Argente J, Batterham RL, Benoit SC, Bowers CY, Broglio F et al (2015) Ghrelin. Mol Metab 4(6):437–460
Tack J, Depoortere I, Bisschops R, Delporte C, Coulie B, Meulemans A, Janssens J, Peeters T (2006) Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 55(3):327–333
De Winter BY, De Man JG, Seerden TC, Depoortere I, Herman AG, Peeters TL, Pelckmans PA (2004) Effect of ghrelin and growth hormone-releasing peptide 6 on septic ileus in mice. J Neurogastroenterol Motil 16(4):439–446
Ejskjaer N, Vestergaard ET, Hellstrom PM, Gormsen LC, Madsbad S, Madsen JL, Jensen TA, Pezzullo JC, Christiansen JS, Shaughnessy L et al (2009) Ghrelin receptor agonist (TZP-101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Aliment Pharmacol Ther 29(11):1179–1187
Koch A, Sanson E, Helm A, Voigt S, Trautwein C, Tacke F (2010) Regulation and prognostic relevance of serum ghrelin concentrations in critical illness and sepsis. Crit Care 14(3):R94
Cummings DE, Overduin J (2004) Circulating Ghrelin levels in pathophysiological conditions. In: Ghigo E (ed) Ghrelin. Springer Science + Business Media, Boston, pp 213–214
Wu R, Dong W, Cui X, Zhou M, Simms HH, Ravikumar TS, Wang P (2007) Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg 245(3):480–486
Wang W, Bansal S, Falk S, Ljubanovic D, Schrier R (2009) Ghrelin protects mice against endotoxemia-induced acute kidney injury. Am J Physiol Renal Physiol 297(4):F1032–F1037
Wu R, Dong W, Qiang X, Wang H, Blau SA, Ravikumar TS, Wang P (2009) Orexigenic hormone ghrelin ameliorates gut barrier dysfunction in sepsis in rats. Crit Care Med 37(8):2421–2426
Wu R, Dong W, Zhou M, Zhang F, Marini CP, Ravikumar TS, Wang P (2007) Ghrelin attenuates sepsis-induced acute lung injury and mortality in rats. Am J Respir Crit Care Med 176(8):805–813
Wu R, Dong W, Zhou M, Cui X, Hank Simms H, Wang P (2005) Ghrelin improves tissue perfusion in severe sepsis via downregulation of endothelin-1. Cardiovasc Res 68(2):318–326
Garin MC, Burns CM, Kaul S, Cappola AR (2013) Clinical review: the human experience with ghrelin administration. J Clin Endocrinol Metab 98(5):1826–1837
Doig GS, Simpson F, Finfer S, Delaney A, Davies AR, Mitchell I, Dobb G (2008) Nutrition Guidelines Investigators of the ACTG: effect of evidence-based feeding guidelines on mortality of critically ill adults: a cluster randomized controlled trial. JAMA 300(23):2731–2741
Poitras P, Peeters TL (2008) Motilin. Curr Opin Endocrinol Diabetes Obes 15(1):54–57
Vantrappen G, Janssens J, Peeters TL, Bloom SR, Christofides ND, Hellemans J (1979) Motilin and the interdigestive migrating motor complex in man. Dig Dis Sci 24(7):497–500
Peeters TL, Muls E, Janssens J, Urbain JL, Bex M, Van Cutsem E, Depoortere I, De Roo M, Vantrappen G, Bouillon R (1992) Effect of motilin on gastric emptying in patients with diabetic gastroparesis. Gastroenterology 102(1):97–101
Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R (1990) Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 322(15):1028–1031
Nguyen NQ, Chapman MJ, Fraser RJ, Bryant LK, Holloway RH (2007) Erythromycin is more effective than metoclopramide in the treatment of feed intolerance in critical illness. Crit Care Med 35(2):483–489
MacLaren R, Kiser TH, Fish DN, Wischmeyer PE (2008) Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. JPEN J Parenter Enteral Nutr 32(4):412–419
Dive A, Miesse C, Galanti L, Jamart J, Evrard P, Gonzalez M, Installe E (1995) Effect of erythromycin on gastric motility in mechanically ventilated critically ill patients: a double-blind, randomized, placebo-controlled study. Crit Care Med 23(8):1356–1362
Gungabissoon U, Hacquoil K, Bains C, Irizarry M, Dukes G, Williamson R, Deane AM, Heyland DK (2015) Prevalence, risk factors, clinical consequences, and treatment of enteral feed intolerance during critical illness. JPEN J Parenter Enteral Nutr 39(4):441–448
Sanger GJ, Wang Y, Hobson A, Broad J (2013) Motilin: towards a new understanding of the gastrointestinal neuropharmacology and therapeutic use of motilin receptor agonists. Br J Pharmacol 170(7):1323–1332
Chapman MJ, Fraser R, Nguyen NQ, Deane AM, O'Conner SN, Duncan R, Hacquoil K, Vasist L, Barton M, Dukes G (2011) The effect of GSK962040, a selective motilin agonist, on gastric emptying in critically ill patients with enteral feed intolerance (Mot112572). Crit Care Med 39(12):195
Pilichiewicz AN, Chaikomin R, Brennan IM, Wishart JM, Rayner CK, Jones KL, Smout AJ, Horowitz M, Feinle-Bisset C (2007) Load-dependent effects of duodenal glucose on glycemia, gastrointestinal hormones, antropyloroduodenal motility, and energy intake in healthy men. Am J Physiol Endocrinol Metab 293(3):E743–E753
Luttikhold J, de Ruijter FM, van Norren K, Diamant M, Witkamp RF, van Leeuwen PA, Vermeulen MA (2013) Review article: the role of gastrointestinal hormones in the treatment of delayed gastric emptying in critically ill patients. Aliment Pharmacol Ther 38(6):573–583
Wank SA (1995) Cholecystokinin receptors. Am J Physiol 269(5 Pt 1):G628–G646
Fried M, Erlacher U, Schwizer W, Lochner C, Koerfer J, Beglinger C, Jansen JB, Lamers CB, Harder F, Bischof-Delaloye A et al (1991) Role of cholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans. Studies with the cholecystokinin-receptor antagonist loxiglumide. Gastroenterology 101(2):503–511
Rayner CK, Park HS, Doran SM, Chapman IM, Horowitz M (2000) Effects of cholecystokinin on appetite and pyloric motility during physiological hyperglycemia. Am J Physiol Gastrointest Liver Physiol 278(1):G98–G104
Nguyen NQ, Fraser RJ, Chapman MJ, Bryant LK, Holloway RH, Vozzo R, Wishart J, Feinle-Bisset C, Horowitz M (2007) Feed intolerance in critical illness is associated with increased basal and nutrient-stimulated plasma cholecystokinin concentrations. Crit Care Med 35(1):82–88
Nguyen NQ, Fraser RJ, Chapman M, Bryant LK, Wishart J, Holloway RH, Horowitz M (2006) Fasting and nutrient-stimulated plasma peptide-YY levels are elevated in critical illness and associated with feed intolerance: an observational, controlled study. Crit Care 10(6):R175
Deane AM, Nguyen NQ, Stevens JE, Fraser RJ, Holloway RH, Besanko LK, Burgstad C, Jones KL, Chapman MJ, Rayner CK et al (2010) Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 95(1):215–221
Plummer MP, Jones KL, Annink CE, Cousins CE, Meier JJ, Chapman MJ, Horowitz M, Deane AM (2014) Glucagon-like peptide 1 attenuates the acceleration of gastric emptying induced by hypoglycemia in healthy subjects. Diabetes Care 37(6):1509–1515
Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA (2005) Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med 202(8):1023–1029
de Haan JJ, Lubbers T, Hadfoune M, Luyer MD, Dejong CH, Buurman WA, Greve JW (2008) Postshock intervention with high-lipid enteral nutrition reduces inflammation and tissue damage. Ann Surg 248(5):842–848
Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B (1996) Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 97(1):92–103
Plummer MP, Chapman MJ, Horowitz M, Deane AM (2014) Incretins and the intensivist: what are they and what does an intensivist need to know about them? Crit Care 18(1):205
Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819–837
Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29(1):46–52
Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46(12):1954–1962
Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Goke B (2006) Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 55(2):243–251
Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR (1999) Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9–39. Diabetes 48(1):86–93
Nauck MA, Heimesaat MM, Behle K, Holst JJ, Nauck MS, Ritzel R, Hufner M, Schmiegel WH (2002) Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87(3):1239–1246
Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D, Knudsen LB (2014) GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155(4):1280–1290
Muscogiuri G, Cignarelli A, Giorgino F, Prodram F, Santi D, Tirabassi G, Balercia G, Modica R, Faggiano A, Colao A (2014) GLP-1: benefits beyond pancreas. J Endocrinol Invest 37:1143–53
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91(1):301–307
Nauck M (1996) Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diabet Med 13(9 Suppl 5):S39–S43
Nauck MA (2009) Unraveling the science of incretin biology. Am J Med 122(6 Suppl):S3–S10
Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87(4):1409–1439
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379
Deane AM, Rayner CK, Keeshan A, Cvijanovic N, Marino Z, Nguyen NQ, Chia B, Summers MJ, Sim JA, van Beek T et al (2014) The effects of critical illness on intestinal glucose sensing, transporters, and absorption. Crit Care Med 42:57–65
Kahles F, Meyer C, Mollmann J, Diebold S, Findeisen HM, Lebherz C, Trautwein C, Koch A, Tacke F, Marx N et al (2014) GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63(10):3221–3229
Summers MJ, DI Bartolomeo AE, Zaknic AV, Chapman MJ, Nguyen NQ, Zacharakis B, Rayner CK, Horowitz M, Deane AM (2014) Endogenous amylin and glucagon-like peptide-1 concentrations are not associated with gastric emptying in critical illness. Acta Anaesthesiol Scand 58(2):235–242
Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, Holst JJ, Ferrannini E (2008) Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 57(5):1340–1348
Nguyen AT, Mandard S, Dray C, Deckert V, Valet P, Besnard P, Drucker DJ, Lagrost L, Grober J (2014) Lipopolysaccharides-mediated increase in glucose-stimulated insulin secretion: involvement of the GLP-1 pathway. Diabetes 63(2):471–482
Nielsen ST, Lehrskov-Schmidt L, Krogh-Madsen R, Solomon TP, Lehrskov-Schmidt L, Holst JJ, Moller K (2013) Tumour necrosis factor-alpha infusion produced insulin resistance but no change in the incretin effect in healthy volunteers. Diabetes Metab Res Rev 29(8):655–663
Combes J, Borot S, Mougel F, Penfornis A (2011) The potential role of glucagon-like peptide-1 or its analogues in enhancing glycaemic control in critically ill adult patients. Diabetes Obes Metab 13(2):118–129
Pinelli NR, Jones MC, Monday LM, Smith Z, Rhoney DH (2012) Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients. Ann Pharmacother 46(1):124–129
Meier JJ, Weyhe D, Michaely M, Senkal M, Zumtobel V, Nauck MA, Holst JJ, Schmidt WE, Gallwitz B (2004) Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 32(3):848–851
Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ Jr, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH et al (2007) Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 100(5):824–829
Deane AM, Summers MJ, Zaknic AV, Chapman MJ, Fraser RJ, Di Bartolomeo AE, Wishart JM, Horowitz M (2011) Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes. Crit Care 15(1):R35
Deane AM, Chapman MJ, Fraser RJ, Summers MJ, Zaknic AV, Storey JP, Jones KL, Rayner CK, Horowitz M (2010) Effects of exogenous glucagon-like peptide-1 on gastric emptying and glucose absorption in the critically ill: relationship to glycemia. Crit Care Med 38(5):1261–1269
Deane AM, Chapman MJ, Fraser RJ, Burgstad CM, Besanko LK, Horowitz M (2009) The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Crit Care 13(3):R67
Galiatsatos P, Gibson BR, Rabiee A, Carlson O, Egan JM, Shannon RP, Andersen DK, Elahi D (2014) The glucoregulatory benefits of glucagon-like peptide-1 (7–36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study. Crit Care Med 42(3):638–645
Abuannadi M, Kosiborod M, Riggs L, House JA, Hamburg MS, Kennedy KF, Marso SP (2013) Management of hyperglycemia with the administration of intravenous exenatide to patients in the cardiac intensive care unit. Endocr Pract 19(1):81–90
Mecott GA, Herndon DN, Kulp GA, Brooks NC, Al-Mousawi AM, Kraft R, Rivero HG, Williams FN, Branski LK, Jeschke MG (2010) The use of exenatide in severely burned pediatric patients. Crit Care 14(4):R153
Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA (2003) Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 46(6):798–801
Deacon CF, Ahren B (2011) Physiology of incretins in health and disease. Rev Diabet Stud 8(3):293–306
Zhou J, Livak MF, Bernier M, Muller DC, Carlson OD, Elahi D, Maudsley S, Egan JM (2007) Ubiquitination is involved in glucose-mediated downregulation of GIP receptors in islets. Am J Physiol Endocrinol Metab 293(2):E538–E547
Hojberg PV, Vilsboll T, Rabol R, Knop FK, Bache M, Krarup T, Holst JJ, Madsbad S (2009) Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 52(2):199–207
Layon AJ, Florete OG Jr, Day AL, Kilroy RA, James PB, McGuigan JE (1991) The effect of duodenojejunal alimentation on gastric pH and hormones in intensive care unit patients. Chest 99(3):695–702
Lee MY, Fraser JD, Chapman MJ, Sundararajan K, Umapathysivam MM, Summers MJ, Zaknic AV, Rayner CK, Meier JJ, Horowitz M et al (2013) The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically ill. Diabetes Care 36(10):3333–3336
Kar P, Cousins CE, Annink CE, Jones KL, Chapman MJ, Meier JJ, Nauck MA, Horowitz M, Deane AM (2015) Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study. Crit Care 19(1):20
Kar P, Jones KL, Horowitz M, Chapman MJ, Deane AM (2015) Measurement of gastric emptying in the critically ill. Clin Nutr 34(4):557–564
Dube PE, Brubaker PL (2007) Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 293(2):E460–E465
Wallis K, Walters JR, Forbes A (2007) Review article: glucagon-like peptide 2--current applications and future directions. Aliment Pharmacol Ther 25(4):365–372
Estall JL, Drucker DJ (2006) Glucagon-like Peptide-2. Annu Rev Nutr 26:391–411
Scott RB, Kirk D, MacNaughton WK, Meddings JB (1998) GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 275(5 Pt 1):G911–G921
Boushey RP, Yusta B, Drucker DJ (1999) Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 277(5 Pt 1):E937–E947
Kouris GJ, Liu Q, Rossi H, Djuricin G, Gattuso P, Nathan C, Weinstein RA, Prinz RA (2001) The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg 181(6):571–575
Prasad R, Alavi K, Schwartz MZ (2000) Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion. J Pediatr Surg 35(2):357–359
Cameron HL, Perdue MH (2005) Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2. J Pharmacol Exp Ther 314(1):214–220
Wilhelm SM, Lipari M, Kulik JK, Kale-Pradhan PB (2014) Teduglutide for the treatment of short bowel syndrome. Ann Pharmacother 48(9):1209–1213
Hernandez G, Velasco N, Wainstein C, Castillo L, Bugedo G, Maiz A, Lopez F, Guzman S, Vargas C (1999) Gut mucosal atrophy after a short enteral fasting period in critically ill patients. J Crit Care 14(2):73–77
Deitch EA (1990) The role of intestinal barrier failure and bacterial translocation in the development of systemic infection and multiple organ failure. Arch Surg 125(3):403–404
Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR (1985) Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89(5):1070–1077
Lin HC, Chey WY, Zhao X (2000) Release of distal gut peptide YY (PYY) by fat in proximal gut depends on CCK. Peptides 21(10):1561–1563
Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA, Bloom SR (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349(10):941–948
Nematy M, O'Flynn JE, Wandrag L, Brynes AE, Brett SJ, Patterson M, Ghatei MA, Bloom SR, Frost GS (2006) Changes in appetite related gut hormones in intensive care unit patients: a pilot cohort study. Crit Care 10(1):R10
Nguyen NQ, Fraser RJ, Bryant LK, Chapman MJ, Wishart J, Holloway RH, Butler R, Horowitz M (2007) The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients. Crit Care 11(6):R132
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Plummer, M.P., Blaser, A.R., Deane, A.M. (2016). Enterohormones and the Response to Critical Illness. In: Preiser, JC. (eds) The Stress Response of Critical Illness: Metabolic and Hormonal Aspects. Springer, Cham. https://doi.org/10.1007/978-3-319-27687-8_13
Download citation
DOI: https://doi.org/10.1007/978-3-319-27687-8_13
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-27685-4
Online ISBN: 978-3-319-27687-8
eBook Packages: MedicineMedicine (R0)